The Spanish Association of Biosimilars will have the advice of Scientific Societies, experts in pharmacology and patient associations
Madrid, 16 June 2016. The Spanish Association of Biosimilars (BioSim) has set up its Advisory Council this morning, the body for consultation and technical and scientific advice for employers.
This committee of experts is made up of Scientific Societies, experts with a recognized track record in fields such as pharmacology or regulatory aspects of the sector, groups of health professionals, as well as representation from Patient Associations.
The meeting of the Advisory Council was chaired by the President of BioSim, Joaquín Rodrigo, who will in turn act as president of this consultative body, who once again highlighted "the open and inclusive nature of BioSim, which we want to permeate all the actions that we carry out as a business association”.
Rodrigo recalled that “our objective is to contribute to improving patient access to highly complex therapies and act as an ally with the Administration in the challenge of ensuring the sustainability of the National Health System; but always acting from dialogue with all parties and promoting scientific criteria above any other”.
In this first meeting, the general director of BioSim, Ángel Luis Rodríguez de la Cuerda, explained to the members of the Advisory Council the regulations that will order the operation of this body, in which express mention is made of respect for the code of good practices of the pharmaceutical industry in all actions carried out by the Council; as well as the constitution of the different working groups that will be created to discuss topics of general interest in the field of biosimilar drugs.
The members that today make up the BioSim Advisory Council are: Jesús Aguilar, president of the CGCOF; Joan Albanell, board of directors of the seom; José Luis Andreu, president of the BEING; Cristina Avendaño, president of the SEFC; Antonio Bernal, president of the AGP; Gonzalo Calvo, pharmacologist the Clinical Hospital of Barcelona; Miguel Ángel Calleja, president of the SEFH; Fernando Carballo, president of the EDPS; Kiko Carrion, lawyer at Eversheds Nicaea; Joaquín Estevez, president of SEDISA; Javier Gisbert, president of GETECCU; Jesus Gomez, President of the SEFAC; José Luis Gómez, member of the SAFE; Beatriz García Cuartero, president of the SEEP; Alvaro Hidalgo, health economist; Ángel Mataix, president of the SEFAP; Fernando deMora, pharmacologist and BioSim scientific advisor; María Dolores del Pino, president of SENEFRO; Manuel Puig, president of the SEEN; Francisco Zaragoza, pharmacologist and professor at the UAH.
BioSim, an open and inclusive association
BioSim was born in November 2015 as a non-profit organization whose will is to represent all pharmaceutical companies established in Spain that develop, manufacture, market or distribute biosimilar medicines. BioSim embraces both biosimilar companies and original biologics companies that have also launched a biosimilar division.
Currently, the 15 companies that make up BioSim are: Accord Biopharmaceuticals, Boehringer Ingelheim, Cinfa Biotech, Gedeon Richter, Kern Pharma, Lilly, mAbxience, Merck, Mylan, Novartis, Rovi, Sandoz, Sanofi, Stada and Teva.
Attached photo caption:
1st Row, from left to right:
- Maria Dolores del Pino (SENEFRO)
- Joaquín Rodrigo (President of BioSim)
- Ángel Luis Rodríguez de la Cuerda (BioSim General Director)
- Jose Luis Andreu (SER)
2st Row, from left to right:
- Beatriz Garcia Cuartero (SEEP)
- Jose Luis Gomez Palomares (SEF)
- Jesus Aguilar (CGCOF)
- Joan Albanell (SEOM)
- Carlos Lens (MSSSI)
- Jesus Gomez (SEFAC)
- Jorge Hinojosa (AGP)
3st Row, from left to right:
- Fernando de Mora (BioSim)
- Joaquin Estevez (SEDISA)
- Javier Gisbert (GETECCU)
- Kiko Carrion (Eversheds Nicea)
- Santiago Pérez (Weber Economy and Health)
